Assessment of cardiovascular safety of anti-osteoporosis drugs

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Fuggle, N.R.
• dc.contributor.author Cooper, Cyrus
• dc.contributor.author Harvey, Nicholas C.
• dc.contributor.author Al-Daghri, N.
• dc.contributor.author Brandi, María Luisa
• dc.contributor.author Bruyère, Olivier
• dc.contributor.author Cano, Albert
• dc.contributor.author Dennison, Elaine
• dc.contributor.author Diez-Perez, Adolfo
• dc.contributor.author Kaufman, J.M.
• dc.contributor.author Palacios, S.
• dc.contributor.author Prieto-Alhambra, Daniel
• dc.contributor.author Rozenberg, S.
• dc.contributor.author Thomas, T.
• dc.contributor.author Tremollieres, F.
• dc.contributor.author Rizzoli, René
• dc.contributor.author Kanis, John A.
• dc.contributor.author Reginster, Jean-Yves
• dc.date.accessioned 2021-06-17T06:53:41Z
• dc.date.available 2021-06-17T06:53:41Z
• dc.date.issued 2020
• dc.description.abstract The incidence of osteoporosis and cardiovascular disease increases with age, and there are potentially shared mechanistic associations between the two conditions. It is therefore highly relevant to understand the cardiovascular implications of osteoporosis medications. These are presented in this narrative review. Calcium supplementation could theoretically cause atheroma formation via calcium deposition, and in one study was found to be associated with myocardial infarction, but this has not been replicated. Vitamin D supplementation has been extensively investigated for cardiac benefit, but no consistent effect has been found. Despite findings in the early 21st century that menopausal hormone therapy was associated with coronary artery disease and venous thromboembolism (VTE), this therapy is now thought to be potentially safe (from a cardiac perspective) if started within the first 10 years of the menopause. Selective estrogen receptor modulators (SERMs) are associated with increased risk of VTE and may be related to fatal strokes (a subset of total strokes). Bisphosphonates could theoretically provide protection against atheroma. However, data from randomised trials and observational studies have neither robustly supported this nor consistently demonstrated the potential association with atrial fibrillation. Denosumab does not appear to be associated with cardiovascular disease and, although parathyroid hormone analogues are associated with palpitations and dizziness, no association with a defined cardiovascular pathology has been demonstrated. Finally, romosozumab has been shown to have a possible cardiovascular signal, and therefore post-market surveillance of this therapy will be vital.
• dc.format.mimetype application/pdf
• dc.identifier.citation Fuggle NR, Cooper C, Harvey NC, Al-Daghri N, Brandi ML, Bruyere O, et al. Assessment of cardiovascular safety of anti-osteoporosis drugs. Drugs. 2020 Oct; 80(15):1537-52. DOI: 10.1007/s40265-020-01364-2
• dc.identifier.doi http://dx.doi.org/10.1007/s40265-020-01364-2
• dc.identifier.issn 0012-6667
• dc.identifier.uri http://hdl.handle.net/10230/47917
• dc.language.iso eng
• dc.publisher SpringerOpen
• dc.rights Copyright © The Author(s) 2020. Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.other Osteoporosi -- Tractament
• dc.subject.other Sistema cardiovascular -- Malalties
• dc.subject.other Menopausa
• dc.title Assessment of cardiovascular safety of anti-osteoporosis drugs
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion